KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Pacific Biosciences Of California (PACB) over the last 17 years, with Q3 2025 value amounting to $803.2 million.

  • Pacific Biosciences Of California's Liabilities and Shareholders Equity fell 4461.18% to $803.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 billion, marking a year-over-year decrease of 4118.3%. This contributed to the annual value of $1.3 billion for FY2024, which is 2781.0% down from last year.
  • Latest data reveals that Pacific Biosciences Of California reported Liabilities and Shareholders Equity of $803.2 million as of Q3 2025, which was down 4461.18% from $825.5 million recorded in Q2 2025.
  • Pacific Biosciences Of California's Liabilities and Shareholders Equity's 5-year high stood at $2.0 billion during Q3 2021, with a 5-year trough of $803.2 million in Q3 2025.
  • For the 5-year period, Pacific Biosciences Of California's Liabilities and Shareholders Equity averaged around $1.6 billion, with its median value being $1.7 billion (2023).
  • As far as peak fluctuations go, Pacific Biosciences Of California's Liabilities and Shareholders Equity skyrocketed by 57733.37% in 2021, and later crashed by 4845.33% in 2025.
  • Quarter analysis of 5 years shows Pacific Biosciences Of California's Liabilities and Shareholders Equity stood at $2.0 billion in 2021, then dropped by 11.95% to $1.8 billion in 2022, then dropped by 1.19% to $1.7 billion in 2023, then fell by 27.81% to $1.3 billion in 2024, then tumbled by 36.28% to $803.2 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $803.2 million for Q3 2025, versus $825.5 million for Q2 2025 and $860.8 million for Q1 2025.